These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 10194100)

  • 1. Fatal infection due to extended-spectrum beta-lactamase-producing Escherichia coli: implications for antibiotic choice for spontaneous bacterial peritonitis.
    Paterson DL; Singh N; Gayowski T; Marino IR
    Clin Infect Dis; 1999 Mar; 28(3):683-4. PubMed ID: 10194100
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical outcomes and therapeutic options of bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    Metan G; Zarakolu P; Cakir B; Hascelik G; Uzun O
    Int J Antimicrob Agents; 2005 Sep; 26(3):254-7. PubMed ID: 16122910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of lower urinary tract infection caused by multidrug-resistant extended-spectrum-beta-lactamase-producing Escherichia coli with amoxicillin/clavulanate: case report and characterization of the isolate.
    Lagacé-Wiens PR; Nichol KA; Nicolle LE; DeCorby M; McCracken M; Mulvey MR; Zhanel GG
    J Antimicrob Chemother; 2006 Jun; 57(6):1262-3. PubMed ID: 16565157
    [No Abstract]   [Full Text] [Related]  

  • 4. Activity in vitro of twelve antibiotics against clinical isolates of extended-spectrum beta-lactamase producing Escherichia coli.
    Sorlózano A; Gutiérrez J; Romero JM; de Dios Luna J; Damas M; Piédrola G
    J Basic Microbiol; 2007 Oct; 47(5):413-6. PubMed ID: 17910106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are beta-lactams related to higher morbidity and mortality in urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli?
    You JH; Kei HW; Lau WC; Wong KY; Marasinghe T; Lee N; Ip M
    J Hosp Infect; 2008 Feb; 68(2):181-3. PubMed ID: 18194826
    [No Abstract]   [Full Text] [Related]  

  • 6. Escherichia coli ST131 producing extended-spectrum β-lactamases plus VIM-1 carbapenemase: further narrowing of treatment options.
    Mantengoli E; Luzzaro F; Pecile P; Cecconi D; Cavallo A; Attala L; Bartoloni A; Rossolini GM
    Clin Infect Dis; 2011 Mar; 52(5):690-1. PubMed ID: 21220769
    [No Abstract]   [Full Text] [Related]  

  • 7. Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli.
    Oteo J; Bautista V; Lara N; Cuevas O; Arroyo M; Fernández S; Lázaro E; de Abajo FJ; Campos J;
    J Antimicrob Chemother; 2010 Nov; 65(11):2459-63. PubMed ID: 20851815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Control of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a children's hospital by changing antimicrobial agent usage policy.
    Lee J; Pai H; Kim YK; Kim NH; Eun BW; Kang HJ; Park KH; Choi EH; Shin HY; Kim EC; Lee HJ; Ahn HS
    J Antimicrob Chemother; 2007 Sep; 60(3):629-37. PubMed ID: 17599919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of beta-lactam and non-beta-lactam antibiotics in extended-spectrum beta-lactamase-producing clinical isolates of Escherichia coli.
    Puerto AS; Fernández JG; del Castillo Jde D; Pino MJ; Angulo GP
    Diagn Microbiol Infect Dis; 2006 Feb; 54(2):135-9. PubMed ID: 16406187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First case of New Delhi metallo-beta-lactamase 1-producing Escherichia coli infection in Japan.
    Chihara S; Okuzumi K; Yamamoto Y; Oikawa S; Hishinuma A
    Clin Infect Dis; 2011 Jan; 52(1):153-4. PubMed ID: 21148536
    [No Abstract]   [Full Text] [Related]  

  • 11. Detection of OXA-2 group extended-spectrum-beta-lactamase-producing clinical isolates of Escherichia coli from India.
    Bhattacharjee A; Sen MR; Anupurba S; Prakash P; Nath G
    J Antimicrob Chemother; 2007 Sep; 60(3):703-4. PubMed ID: 17623688
    [No Abstract]   [Full Text] [Related]  

  • 12. Molecular characterization of plasmids encoding CTX-M-15 extended-spectrum beta-lactamase associated with the ST131 Escherichia coli clone in Belgium.
    Montesinos I; Rodriguez-Villalobos H; De Mendonça R; Bogaerts P; Deplano A; Glupczynski Y
    J Antimicrob Chemother; 2010 Aug; 65(8):1828-30. PubMed ID: 20534625
    [No Abstract]   [Full Text] [Related]  

  • 13. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.
    Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4574-81. PubMed ID: 15561828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infections due to Escherichia coli producing extended-spectrum beta-lactamase among hospitalised patients: factors influencing mortality.
    Peña C; Gudiol C; Calatayud L; Tubau F; Domínguez MA; Pujol M; Ariza J; Gudiol F
    J Hosp Infect; 2008 Feb; 68(2):116-22. PubMed ID: 18226420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli.
    Bin C; Hui W; Renyuan Z; Yongzhong N; Xiuli X; Yingchun X; Yuanjue Z; Minjun C
    Diagn Microbiol Infect Dis; 2006 Dec; 56(4):351-7. PubMed ID: 16934430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes.
    Lautenbach E; Patel JB; Bilker WB; Edelstein PH; Fishman NO
    Clin Infect Dis; 2001 Apr; 32(8):1162-71. PubMed ID: 11283805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Community-acquired extended-spectrum beta-lactamase producers, United States.
    Doi Y; Adams J; O'Keefe A; Quereshi Z; Ewan L; Paterson DL
    Emerg Infect Dis; 2007 Jul; 13(7):1121-3. PubMed ID: 18214201
    [No Abstract]   [Full Text] [Related]  

  • 18. Susceptibility pattern of extended-spectrum beta-lactamase producing bacteria isolated from inpatients to five antimicrobial drugs in a community hospital in Northern Israel.
    Colodner R; Raz R; Chazan B; Sakran W
    Int J Antimicrob Agents; 2004 Oct; 24(4):409-10. PubMed ID: 15380271
    [No Abstract]   [Full Text] [Related]  

  • 19. Dissemination of extended-spectrum β-lactamase-producing Escherichia coli at home: a potential occupational hazard for healthcare workers?
    Cotter M; Boyle F; Khan A; Boo TW; O'Connell B
    J Hosp Infect; 2012 Jan; 80(1):100-1. PubMed ID: 22112534
    [No Abstract]   [Full Text] [Related]  

  • 20. In the literature. Piperacillin-tazobactam and extended-spectrum β-lactamase--producing Escherichia coli.
    Clin Infect Dis; 2013 Nov; 57(10):iii-iv. PubMed ID: 24308040
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.